Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial of Weekly Paclitaxel/Bevacizumab +/- Everolimus as First-Line Chemotherapy for Patients With HER2-Negative Metastatic Breast Cancer (MBC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Everolimus (Primary) ; Bevacizumab; Paclitaxel
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- 28 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Sep 2014 Planned End Date changed from 1 Jul 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 18 Jun 2014 Planned End Date changed from 1 Jun 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov.